Overview of Stage III NSCLC

Webcast of a CCO symposium at CHEST 2019 featuring expert perspectives on optimal integration of immunotherapy into stage III NSCLC care using a multidisciplinary approach

Gerard A. Silvestri, MD, MS
Program Director Kristin Higgins, MD Mark A. Socinski, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ US Physicians: maximum of 1.0 Medical Knowledge MOC point(s) Released: November 20, 2019 Expired: No longer available for credit

In this slideset, a multidisciplinary expert panel reviews the latest clinical data supporting the optimal use of checkpoint inhibitor therapy for stage III NSCLC.

Gerard A. Silvestri, MD, MS
Program Director Kristin Higgins, MD Mark A. Socinski, MD Released: October 21, 2019

In this slideset, a multidisciplinary expert panel provides insights on optimal use of checkpoint inhibition in the treatment of a series of patient cases with stage III NSCLC.

Gerard A. Silvestri, MD, MS
Program Director Kristin Higgins, MD Mark A. Socinski, MD Released: October 21, 2019